Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
FAQ
What is the current stock price of Editas Medicine (EDIT)?
Editas Medicine (EDIT) last closed at $2.95.
What is the market cap of Editas Medicine (EDIT)?
The market cap of Editas Medicine (EDIT) is approximately $453.1M.